Clinical Trial

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Study acronym: CYPIDES
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-10-31 2026-08-15
minor Completion pushed: 2026-07-31 -> 2026-10-31 2026-08-15
Trial Details
NCT Number NCT03436485
Lead Sponsor Orion Corporation, Orion Pharma
Conditions Prostate Cancer Metastatic
Enrollment 204 participants
Start Date 2018-03-19
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14